High-dose Chemotherapy With Hematopoietic Stem-cell Rescue for High-risk Breast Cancer: Long-term Follow-up

Conditions

Breast Cancer Female

Brief summary

Collection of follow-up data from the original trial patient cohort.

Detailed description

Collection of follow-up data from the original trial patient cohort by means of structured patient file abstraction, a questionnaire to the general practitioner, and registry consultations.

Vliek S, Hilbers FS, van Werkhoven E, Mandjes I, Kessels R, Kleiterp S, Lips EH, Mulder L, Kayembe MT, Loo CE, Russell NS, Vrancken Peeters MTFD, Holtkamp MJ, Schot M, Baars JW, Honkoop AH, Vulink AJE, Imholz ALT, Vrijaldenhoven S, van den Berkmortel FWPJ, Meerum Terwogt JM, Schrama JG, Kuijer P, Kroep JR, van der Padt-Pruijsten A, Wesseling J, Sonke GS, Gilhuijs KGA, Jager A, Nederlof P, Linn SC.

2023-09-095 citations

10.1038/s41523-023-00580-9

Predictive value of ectopic <i>HORMAD1</i> tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer.

L. De Boo, Jelmar Quist, Mark Opdam, Katarzyna Jóźwiak, Patrycja Gazińska et al. (16 authors)

Journal of Clinical Oncology2022-06-01

10.1200/jco.2022.40.16_suppl.541

High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes

Tessa G. Steenbruggen, Lars C. Steggink, Caroline Seynaeve, Jacobus J. M. van der Hoeven, Maartje J. Hooning et al. (21 authors)

JAMA Oncology2020-01-3031 citations

10.1001/jamaoncol.2019.6276

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Enrolment in the original trial.

Exclusion criteria

* None.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	2 years	Overall survival according to the definition and analysis plan of the original study
Relapse-free survival	2 years	Relapse-free survival according to the definition and analysis plan of the original study

Secondary

Measure	Time frame
Incidence of cardiovascular events	2 years
Incidence of malignancies	2 years

Countries

Netherlands

Outcome results